Interstitial Lung Disease Induced by Anti-TNF Agents (31-08-07)

a) Reported cases

First author	Year	Patients	Age	Gender	Rheumatic disease	Anti-TNF administered
Hagiwara	2007	1	70	F	RA	Etanercept
Huggett	2007	1	76	F	RA	Adalimumab
Kudrin	2007	1	52	F	RA	Etanercept
Wolfe	2007	1	NE	NE	RA	Infliximab
Almodóvar	2007	1	34	M	AS	Infliximab
Vavricka	2007	1	73	M	RA	Etanercept
Verschveren	2007	1	46	F	RA	Etanercept
Verschveren	2007	1	53	F	RA	Etanercept
Mori	2007	1	66	F	RA	Infliximab
Lindsay	2007	1	64	F	RA	Etanercept
Lindsay	2007	1	61	F	RA	Etanercept
Allamore	2006	1	74	F	SSc	Adalimumab
O'Shea	2006	1	34	M	AS	Infliximab
Pataka	2006	1	75	M	AS	Infliximab
Hennum	2006	1	59	F	RA	Infliximab
Weatherhead	2006	1	NE	NE	CD	Infliximab
Gonzalez-Lopez	2006	1	70	M	AS	Etanercept
Villeneuve	2006	1	70	M	RA	Infliximab
Kang	2006	1	55	F	RA	Etanercept
Schoe	2006	1	67	M	RA	Adalimumab
Quintos-Macasa	2006	1	NE	NE	RA	Etanercept
Philips	2005	1	37	M	PsA	Etanercept
Martin	2005	1	60	F	Still	Infliximab
De Bandt	2005	1	NE	F	RA	Infliximab
Panagi	2004	1	NE	NE	CD	Infliximab
Chaterjee	2004	1	84	F	RA	Infliximab
Ostor	2003	1	67	M	RA	Infliximab
Ostor	2003	2	61	F	RA	Infliximab
Ostor	2003	3	75	F	RA	Infliximab
Ostor	2003	4	68	F	RA	Infliximab
Ostor	2003	5	49	F	RA	Infliximab
Courtney	2003	1	72	F	RA	Infliximab
Kramer	2003	1	68	F	RA	Infliximab
Kramer	2002	1	64	F	RA	Infliximab
Kramer	2002	2	63	F	RA	Infliximab
Kramer	2002	3	80	F	RA	Infliximab

a) Classification